ALK and non-small cell lung carcinoma: Brigatinib (BGT) is a second-generation anaplastic lymphoma kinase (ALK) inhibitor that is used to treat a certain type of non-small cell lung cancer (NSCLC) by inhibiting an abnormal protein that causes cancer cells to multiply [5,6,7].